Company Description
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States.
It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
The company’s product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases.
The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam’s proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells.
The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018.
Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
| Country | United States |
| Founded | 2018 |
| IPO Date | Feb 4, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 142 |
| CEO | Steven Harr |
Contact Details
Address: 188 East Blaine Street, Suite 400 Seattle, Washington 98102 United States | |
| Phone | 206 701 7914 |
| Website | sana.com |
Stock Details
| Ticker Symbol | SANA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $25.00 |
| CIK Code | 1770121 |
| CUSIP Number | 799566104 |
| ISIN Number | US7995661045 |
| Employer ID | 83-1381173 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Steven D. Harr M.D. | President, Chief Executive Officer and Director |
| Brian D. Piper M.B.A. | Executive Vice President and Chief Financial Officer |
| Susan Wyrick | Treasurer, Principal Accounting Officer and Senior Vice President of Finance and Accounting |
| Snehal Patel | Senior Vice President and Chief Technical Officer |
| Dr. Dhavalkumar D. Patel M.D., Ph.D. | Executive Vice President and Chief Scientific Officer |
| Aaron M. Grossman | Executive Vice President and Chief Legal Officer |
| Dr. Gary Meininger M.D. | Chief Medical Officer |
| Dr. Yuko Soneoka J.D., Ph.D. | Head of Intellectual Property |
| John Gerecitano M.D., Ph.D. | Head of Oncology Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 3, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Mar 3, 2026 | 10-K | Annual Report |
| Mar 3, 2026 | 8-K | Current Report |
| Feb 17, 2026 | 8-K | Current Report |
| Jan 21, 2026 | SCHEDULE 13G | Filing |
| Jan 14, 2026 | 8-K | Current Report |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 6, 2025 | 10-Q | Quarterly Report |
| Nov 6, 2025 | 8-K | Current Report |
| Sep 10, 2025 | UPLOAD | Filing |